

# Structure-Activity Relationship Studies of the Two-Component Lantibiotic Haloduracin

Lisa E. Cooper,<sup>1,3</sup> Amanda L. McClerren,<sup>2,3</sup> Anita Chary,<sup>2</sup> and Wilfred A. van der Donk<sup>1,2,\*</sup>

<sup>1</sup>Department of Biochemistry

<sup>2</sup>Department of Chemistry

University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801, USA

<sup>3</sup>These authors contributed equally to this work

\*Correspondence: vddonk@uiuc.edu

DOI 10.1016/j.chembiol.2008.07.020

## SUMMARY

The lantibiotic haloduracin consists of two post-translationally processed peptides, Hal $\alpha$  and Hal $\beta$ , which act in synergy to provide bactericidal activity. An in vitro haloduracin production system was used to examine the biological impact of disrupting individual thioether rings in each peptide. Surprisingly, the Hal $\alpha$  B ring, which contains a highly conserved CTLXEC motif, was expendable. This motif has been proposed to interact with haloduracin's predicted target, lipid II. Exchange of the glutamate residue in this motif for alanine or glutamine completely abolished antibacterial activity. This study also established that Hal $\alpha$ -Ser26 and Hal $\beta$ -Ser22 escape dehydration, requiring revision of the Hal $\beta$  structure previously proposed. Extracellular proteases secreted by the producer strain can remove the leader peptide, and the Hal $\alpha$  cystine that is dispensable for bioactivity protects Hal $\alpha$  from further proteolytic degradation.

## INTRODUCTION


Lantibiotics are a class of cyclic peptides produced by Gram-positive bacteria. They are ribosomally synthesized as inactive precursor peptides that undergo posttranslational modification to generate their mature, biologically active forms. More than 50 lantibiotics are known to date, most of which function as antimicrobial peptides (Chatterjee et al., 2005b; Cotter et al., 2005; Willey and van der Donk, 2007). Notably, the most extensively studied member, nisin, has been used worldwide for decades in the food industry without the development of widespread antibiotic resistance (Delves-Broughton et al., 1996). Moreover, other lantibiotics, such as mersacidin, lacticin 3147, and microbisporicin, are effective against methicillin-resistant *Staphylococcus aureus* and other multidrug-resistant pathogens (Castiglione et al., 2008; Galvin et al., 1999; Kruszewska et al., 2004).

All lantibiotics contain the characteristic lanthionine (Lan) and/or methyllanthionine residues (MeLan), and also typically the unsaturated amino acids dehydroalanine (Dha) and dehydrobutyrine (Dhb) that are introduced by posttranslational modification. Lantibiotic precursor peptides (LanA) consist of a structural

region that will be transformed into the antimicrobial peptide and an N-terminal leader sequence that does not undergo modification. Specific Ser and Thr residues in the structural region are enzymatically dehydrated to yield Dha and Dhb, respectively (Figure 1). Through a Michael-type addition, Cys residues react with these dehydro amino acids to form the thioether rings, Lan from Ser and MeLan from Thr. The precise roles of the leader peptide are still under debate (Ferguson Ihnken et al., 2008; Levensgood et al., 2007; Patton et al., 2008), but following modification it must be removed by proteolysis to generate the active lantibiotic (Chen et al., 2001; Corvey et al., 2003; Li et al., 2006; McClerren et al., 2006; van der Meer et al., 1994; Xie et al., 2004).

A subclass of lantibiotics consists of the two-peptide systems. These compounds are formed from two precursor peptides posttranslationally modified to create two distinct products that act in synergy to provide bactericidal activity (Garneau et al., 2002). Currently, seven two-component lantibiotics are known, including the best-studied example, lacticin 3147 (Ryan et al., 1999), and the most recently identified member, haloduracin (Lawton et al., 2007; McClerren et al., 2006). For haloduracin, produced by the Gram-positive alkaliphilic bacterium *Bacillus halodurans* C-125, the unmodified peptides HalA1 and HalA2 are each dehydrated and cyclized by two dedicated bifunctional enzymes, HalM1 and HalM2, respectively. During this process, one of the four Ser/Thr residues in the structural region of HalA1 and one of the eight Ser/Thr residues in the structural peptide of HalA2 escape dehydration by their respective modification enzymes. Proteolytic removal of the leader peptide results in the mature, active components, Hal $\alpha$  and Hal $\beta$ . The HalA1 peptide is predicted to have 32% and 44% amino acid sequence identity with the precursor peptides from mersacidin (P43683) and lacticin 3147 A1 (O87236), respectively. Both mersacidin and the mature A1 component of lacticin 3147 bind to lipid II, an essential precursor in peptidoglycan biosynthesis (Brötz et al., 1998; Wiedemann et al., 2006). A sequential model has been proposed for the bactericidal action of two-peptide lantibiotics in which the  $\alpha$  (A1) peptide first binds to lipid II and the  $\alpha$ :lipid II complex serves as a docking site for the  $\beta$  (A2) peptide. Once recruited, the extended conformation of the  $\beta$  component is believed to facilitate pore formation in the bacterial membrane (Morgan et al., 2005; Wiedemann et al., 2006).

Herein, the structural features essential for biological activity of haloduracin were investigated using a recently developed in vitro biosynthetic system (McClerren et al., 2006). A number of haloduracin analogs were constructed and the impact of the



**Figure 1. General Overview of the Common Steps in Lantibiotic Biosynthesis**

LanA, lantibiotic precursor peptide.

alterations on antibiotic activity was assessed. In addition, this study suggests that some or all of the proteolytic process that removes the leader peptides may be performed by extracellular proteases secreted by the *B. halodurans* producing strain.


## RESULTS

### Structures of Hal $\alpha$ and Hal $\beta$

Based on the mass of haloduracin prepared enzymatically in vitro as well as the products isolated from *B. halodurans* C-125, one Ser/Thr residue escapes dehydration in both Hal $\alpha$  and Hal $\beta$  (McClerren et al., 2006). To identify the locations of these residues and to examine their biological significance, specific Ser/Thr residues were mutated in the substrate peptides to Ala. The mutant substrates were subjected to HalM1 or HalM2 and analyzed by MALDI-TOF MS. For HalA1, three of four resi-

dues undergo dehydration. Comparison of its sequence to that of other lantibiotics suggested that Ser26 escaped dehydration (McClerren et al., 2006; Figure 2A). To test this hypothesis the S26A mutant of HalA1-Xa was constructed by site-directed mutagenesis and processed in vitro with HalM1. As discussed previously (McClerren et al., 2006), this substrate contains a Factor Xa recognition site for leader peptide removal. Upon subjection to HalM1 under standard assay conditions (McClerren et al., 2006), three dehydrations were still observed by MS (see Figure S1A available online), thus indicating that Ser26 is indeed the residue that is not acted upon by HalM1. For Hal $\beta$ , it was established that seven of eight Ser/Thr residues undergo dehydration in the structural region of HalA2 (McClerren et al., 2006). Based on homology to other lantibiotics it was proposed that Thr18 was not dehydrated. However, when the T18A mutant of HalA2-Xa was treated with HalM2, a product with 6-fold dehydration was observed (Figure S1B). This finding strongly suggests that Thr18 is normally dehydrated by HalM2. FTMS/MS data obtained previously narrowed down the other possible candidates for the residue that is not dehydrated to Thr17, Thr21, or Ser22 (McClerren et al., 2006). Thr17 and Thr21 are believed to be involved in methyllanthionine rings that are highly conserved in two-component lantibiotics (McClerren et al., 2006). Thus, HalA2-Xa S22A was constructed and subjected to HalM2 catalysis. MS analysis showed that this mutant was dehydrated 7-fold (Figure 3), demonstrating that Ser22 escapes dehydration by HalM2 in wild-type HalA2. The structure for Hal $\beta$  has been revised to reflect these data (Figure 2B).

The cyclization reaction is more difficult to examine because it does not involve a change in mass. In previous studies, techniques were developed that report on noncyclized cysteines through derivatization of their thiol groups (Li and van der Donk, 2007; Li et al., 2006; McClerren et al., 2006; Paul et al., 2007). Control reactions with unmodified HalA1 and HalA2 substrates indicated that iodoacetamide (IAA) was more effective for HalA1, whereas *p*-hydroxymercuribenzoic acid (PHMB) (Li and van der Donk, 2007; Paul et al., 2007; Pitts and Summers, 2002) showed better derivatization efficiency for HalA2. Hence, throughout this study IAA was used to test cyclization of HalA1 mutants, and PHMB was used for HalA2. The reasons behind the different derivatization efficiency of these peptides were not investigated but are likely related to their different solubilities. The products of the enzyme assays with HalA1-Xa S26A, HalA2-Xa T18A, and HalA2-Xa S22A were treated with reductant followed by thiol derivatizing agent and monitored by MALDI-TOF MS, showing that none of the assay products displayed adducts (beyond the two expected for the cysteine residues of the disulfide in Hal $\alpha$ ) and demonstrating that these mutants were cyclized (Figure S1C–E). Removal of the leader peptide for evaluation of antimicrobial activity of the haloduracin analogs produced was accomplished using the previously described Factor Xa engineered system (McClerren et al., 2006). Briefly, in substrates denoted HalA1/2-Xa, the four amino acids in the leader peptides immediately prior to the structural region of HalA1 (Val-Asn-Gly-Ala) and HalA2 (Val-His-Ala-Gln) were replaced with the Factor Xa recognition site (Ile-Glu-Gly-Arg; Figure 2). After treatment of the HalM1 and HalM2 enzymatic products with Factor Xa and confirmation of proteolytic processing by MALDI-TOF MS, agar diffusion assays against a haloduracin-sensitive strain,



*Lactococcus lactis* CNRZ 117, were performed. The data showed that the two residues that escape dehydration (Hal $\alpha$  Ser26 and Hal $\beta$  Ser22) are not necessary for antibacterial activity as replacement with Ala still resulted in zones of growth inhibition. Furthermore, when an Ala residue was installed in place of Dhb18 of Hal $\beta$ , bioactivity was retained (Figure 4, regions 14–16).

### Thioether Ring Disruption in Hal $\alpha$ and Hal $\beta$

To evaluate the significance of each sulfide ring in Hal $\alpha$  and Hal $\beta$ , they were disrupted individually by converting Cys residues to Ala in the substrate peptides. Previously it was shown that the cystine linkage in Hal $\alpha$  was not required for bacterial growth inhibition (McClerren et al., 2006). Even when the Cys thiols were alkylated by treatment with iodoacetamide (IAA), a zone of inhibition was observed in agar diffusion assays. The nonessential nature of the cystine was confirmed in this study by generation of the HalA1-Xa C8A peptide and incubation with HalM1, resulting in a 3-fold dehydrated product (Figure 5A). Subsequent analysis with IAA for cyclization as discussed previously showed that the mutant contained a single reactive Cys (Cys1), indicating that three Cys residues were unavailable for alkylation (Figure 5B), a result consistent with formation of three thioether rings. The HalM1 product was treated with Factor Xa protease to remove

### Figure 2. Biosynthesis of Hal $\alpha$ and Hal $\beta$


(A and B) In substrates designated HalA1-Xa or HalA2-Xa, the four amino acids at positions –1 to –4 were replaced by IEGR (boxed in blue). In (B), the revised structure of Hal $\beta$  is shown based on the results in this study.

the leader sequence, and tested against the bacterial indicator strain, resulting in a zone of inhibition (Figure 4, region 3) and confirming that the disulfide is dispensable.

Using a similar strategy, the A, B, and C rings were disrupted by mutating Cys17, Cys23, and Cys27 of HalA1-Xa to Ala, respectively. MALDI-TOF MS analysis of the assay products prepared by incubation of the HalA1-Xa Cys-to-Ala mutants with HalM1 showed that 3-fold dehydration occurred for all (Figure S2), and IAA analysis revealed that all of these HalM1-processed mutants contained two reactive Cys residues corresponding to Cys1 and Cys8. The IAA derivatization studies suggest that all other Cys residues underwent the anticipated cyclization in these mutants. Subsequent removal of the leader peptide and qualitative antimicrobial assays showed that the C ring was essential for bioactivity because the C27A mutant did not produce a zone of inhibition (Figure 4, region 6). Surprisingly, the B ring proved to be

expendable as Hal $\alpha$ -C23A gave a clear inhibition zone when antibiotic activity was assessed in three independent experiments (Figure 4, region 5). A small but reproducible zone was observed for the C17A mutant, suggesting the A ring is important but not absolutely essential (region 4).

Evaluation of the importance of the Lan and MeLan rings in Hal $\beta$  was similarly completed. The A, B, C, and D rings were individually disrupted by conversion of Cys5, Cys15, Cys20, and Cys24 of HalA2-Xa to Ala, respectively. Incubation with HalM2 and analysis by MALDI-TOF MS revealed seven dehydrations for all four mutants as shown for the C5A mutant in Figure 5C (for all other mutants, see Figure S3). Subsequent analysis with PHMB for cyclization showed that the mutants C5A, C20A, and C24A did not contain any free thiols, suggesting they underwent complete cyclization as shown for C5A in Figure 5D (for other mutants, see Figure S3). However, C15A did display multiple adducts derived from PHMB (Figure S3C), indicating that disruption of the B ring also affected ring formation of one or more of the other rings. The consequences of removal of one or more rings on antimicrobial activity were evaluated by agar diffusion assays after leader peptide removal. The mutant that lacked the A ring (C5A) retained antibiotic activity (Figure 4, region 8). No zone of inhibition was observed for the C15A mutant of Hal $\beta$ , and only weak zones of growth inhibition



**Figure 3. MALDI-TOF MS of HalA2-Xa S22A**  
HalA2-Xa S22A before (dashed line) and after (solid line) incubation with HalM2. The asterisks (\*) indicate a phosphorylated peptide (Chatterjee et al., 2005a).

were observed for the C20A and C24A mutants (Figure 4, regions 9–11).

#### A Highly Conserved Glutamate Residue in Hal $\alpha$ Is Essential for Bioactivity

It was recently shown that a highly conserved glutamate in mersacidin (Glu17) was essential for binding to its target lipid II (Brötz et al., 1998; Hsu et al., 2003; Szekat et al., 2003). Because of the high degree of homology between the C ring of mersacidin and the B ring of Hal $\alpha$  (Figure 6A), the corresponding Glu22 could play a similar role in the mode of action of haloduracin. Therefore, Glu22 in HalA1-Xa was mutated to Ala and Gln. Upon treatment with HalM1, these mutants underwent three dehydrations as expected (Figure 6B). Cyclization was confirmed using IAA treatment under reducing conditions followed by MS analysis. The two IAA adducts observed were assigned to the two Cys residues that form the disulfide ring of HalA1-Xa (Figure 6C). Bioactivity analysis after removal of the leader peptide with Factor Xa showed that antibacterial activity was completely abolished under the conditions used (Figure 4, regions 12 and 13).


#### Proteolytic Processing

Leader peptide removal for HalA1 and HalA2 is proposed to be achieved *in vivo* by a single enzyme termed HalT (Lawton et al., 2007; McClerren et al., 2006). The predicted cleavage site for LanT protease domains is after a double-Gly recognition motif (GG, GA, or GS sequences; Håvarstein et al., 1995; Nes and Tagg, 1996). For HalA1, proteolysis behind the predicted cleavage site Gly-2Ala-1 (Figure 2A) was confirmed by mass spectrometry on haloduracin  $\alpha$  produced by *B. halodurans* C-125 (McClerren et al., 2006). For HalA2, the cleavage was predicted

to take place after Gly-8Ser-7 (Figure 2B), yet the mass spectrometric data on Hal $\beta$  produced by *B. halodurans* C-125 showed that residues Gly-6 through Gln-1 were also removed (Figure 2B). Therefore, if HalT cleaves after the GlySer sequence, then an additional N-terminal proteolytic step must occur. The biological significance of the removal of the residues GDVHAQ was examined by the generation of a mutant of HalA2, designated HalA2-XaGS, with the Factor Xa cleavage signal immediately following the predicted HalT cleavage signal at Gly-8Ser-7 (Figure S4A). This construct was incubated with HalM2 to yield the expected 7-fold dehydrated product (Figure S4B) and was further processed by treatment with Factor Xa. When the resulting product designated GDVHAQ-

Hal $\beta$  was tested for antibiotic activity in the presence of Hal $\alpha$ , inhibition zones comparable to *in vivo* and *in vitro* prepared haloduracin were observed (Figure S4D). This data indicated that the additional six amino acids on the N terminus of this mutant product do not interfere with the bioactivity of haloduracin.

We investigated the possibility that N-terminal trimming of the GDVHAQ-Hal $\beta$  product occurred on the agar plate by extracellular proteases from the reporter strain during the bioassay, and that the trimmed Hal $\beta$  product was actually responsible for the observed zone of inhibition. Furthermore, we investigated whether the producer strain *B. halodurans* C-125 secretes a protease that could perform N-terminal trimming of longer Hal $\beta$  products. For this purpose, the HalA2-XaGS Q23A mutant was generated. The Q23A mutation was introduced so that Hal $\beta$  generated by processing of GDVHAQ-Hal $\beta$  could be distinguished from Hal $\beta$  produced endogenously by *B. halodurans* C-125. This mutation was chosen because an Ala is present at this position in lactacin 3147 A2. The peptide was expressed in *E. coli*, purified, and subjected to HalM2 modification, resulting in seven dehydrations and complete cyclization (Figures S5A and S5B). Subsequent Factor Xa cleavage yielded GDVHAQ-Hal $\beta$  Q23A as observed by MALDI-TOF MS. Incubation with the *L. lactis* CNRZ 117 indicator strain did not result in processing of GDVHAQ-Hal $\beta$  Q23A (Figure 7A). However, the culture supernatant from the *B. halodurans* C-125 producer strain did contain one or more proteases that cleanly removed the GDVHAQ sequence, resulting in Hal $\beta$  Q23A (Figure 7A). In a second experiment, full-length HalA2-XaGS Q23A processed by HalM2 was incubated with the culture supernatant. Once more, proteolytic processing occurred, removing the entire leader sequence and producing Hal $\beta$  Q23A (Figure 7B). To examine the fate of Hal $\alpha$



**Figure 4. Antimicrobial Activity Assays for Haloduracin Mutants against the Indicator Strain *L. lactis* CNRZ 117**

In vitro refers to compound produced with purified HalM enzymes and subsequent proteolysis with Factor Xa. In vivo refers to Hal $\alpha$  or Hal $\beta$  isolated and purified from *B. halodurans* C-125. Region 1, Hal $\alpha$  + Hal $\beta$  (both in vivo); region 2, Hal $\alpha$  (in vitro) and Hal $\beta$  (in vivo); region 3, Hal $\alpha$  C8A (in vitro) + Hal $\beta$  (in vivo); region 4, Hal $\alpha$  C17A (in vitro) + Hal $\beta$  (in vivo); region 5, Hal $\alpha$  C23A (in vitro) + Hal $\beta$  (in vivo); region 6, Hal $\alpha$  C27A (in vitro) + Hal $\beta$  (in vivo); region 7, Hal $\alpha$  (in vivo) + Hal $\beta$  (in vitro); region 8, Hal $\alpha$  (in vivo) + Hal $\beta$  C5A (in vitro); region 9, Hal $\alpha$  (in vivo) + Hal $\beta$  C15A (in vitro); region 10, Hal $\alpha$  (in vivo) + Hal $\beta$  C20A (in vitro); region 11, Hal $\alpha$  (in vivo) + Hal $\beta$  C24A (in vitro); region 12, Hal $\alpha$  E22A (in vitro) + Hal $\beta$  (in vivo); region 13, Hal $\alpha$  E22Q (in vitro) + Hal $\beta$  (in vivo); region 14, Hal $\alpha$  S26A (in vitro) + Hal $\beta$  (in vivo); region 15, Hal $\alpha$  (in vivo) + Hal $\beta$  Dhb18Ala (in vitro); region 16, Hal $\alpha$  (in vivo) + Hal $\beta$  S22A (in vitro).

under these conditions, purified Hal $\alpha$  was incubated with the culture supernatant of *B. halodurans* C-125 with and without pretreatment with the reductant tris(2-carboxyethyl)phosphine (TCEP) to reduce the N-terminal disulfide and subsequent alkylation by IAA. Interestingly, the Hal $\alpha$  that was not treated with TCEP/IAA did not undergo any proteolysis as judged by MALDI-TOF MS (Figure S5D), but the sample preincubated with TCEP/IAA was proteolytically processed to peptides corresponding to loss of the N-terminal three and five amino acids (Figure 7C).


## DISCUSSION

The ribosomal origin of the lantibiotics has provided a convenient means to conduct structure-activity relationship studies via the generation of analogs by mutagenesis of the prepeptides. Such mutagenesis studies have been carried out both in vivo in the producer strains or a suitable heterologous host, and in reconstituted in vitro systems (Chatterjee et al., 2005b; Cotter et al., 2005; Lubelski et al., 2008). In this study, haloduracin mutants were produced in vitro and analyzed for antibacterial activity with a focus on the posttranslational modifications. The outcome with the S26A mutant of HalA1 confirmed the previous hypothesis based on sequence homology with other lantibiotics that this residue is not dehydrated in Hal $\alpha$ . However, the findings with both HalA2 T18A and S22A mutants are inconsistent with the previously proposed structure of Hal $\beta$  based on sequence homology (McClerren et al., 2006). Both mutants strongly suggest that Ser22 in Hal $\beta$  is not dehydrated, a result that was confirmed for wild-type HalA2 by postsourc decay MS in a study on the directionality and processivity of HalM2 (unpublished data). The observation that the residues that escape dehydration in both Hal $\alpha$  and Hal $\beta$  are serines is in line with a previous study that compared all known lantibiotics and concluded that Ser residues escape dehydration with a much higher frequency than Thr residues (Rink et al., 2005). The underlying reason for this trend is

not known. In the case of haloduracin, the flanking residues of Ser26 in Hal $\alpha$  (Pro and Cys) and Ser22 in Hal $\beta$  (Thr/Dhb and Gln) are not obvious deactivating residues. For instance, a Pro flanking Thr17 and Thr/Dhb flanking Thr2 and Thr17 in HalA2 did not negatively affect dehydration by HalM2. Although the molecular logic of why lantibiotic synthetases sometimes skip a Ser/Thr is not known, a potential evolutionary reason could be that the unmodified Ser/Thr in question is important for the biological activity of the final compound. It appears, however, that this is not the case for Ser26 in Hal $\alpha$  and Ser22 in Hal $\beta$ , as shown by antimicrobial assays of analogs in which these residues were mutated. Similarly, the Thr17, Thr19, and Thr23 residues that remain unmodified in lactacin 3147 A2 (but have no homologous residues in haloduracin) were not critical for its biological activity (Cotter et al., 2006).

The corollary of Ser22 escaping dehydration in Hal $\beta$  is that Thr18 must be dehydrated, in contrast to the homologous residue in lactacin 3147 A2 (Thr23), which is not dehydrated according to NMR studies (Martin et al., 2004). The differences between these two lantibiotics illustrate that the use of sequence homology to predict the structure of lantibiotics is perilous. This finding is relevant for the currently structurally uncharacterized two-component lantibiotics Smb and BHT for which the genes were recently reported. These predict 7 (BHT) or 8 (Smb) Ser/Thr in the A-peptide and 7 Ser/Thr in the B peptide (Hyink et al., 2005; Yonezawa and Kuramitsu, 2005) (Figure S6), but the masses observed for the mature peptides suggest only five of these residues are dehydrated in each peptide for Smb (Petersen et al., 2006). The BHT/Smb peptides have sequence homology with both haloduracin and lactacin 3147 (Figure S6), but based on the structures of these two lantibiotics it cannot be concluded which residues escape dehydration in Smb/BHT.

The thioether rings in lantibiotics are believed to be the basis for their biological activity, and in general, disruption of a ring results in abolishment of antimicrobial activity (Bierbaum et al., 1996; Chatterjee et al., 2005b, 2006; Chen et al., 1998; Kuipers et al.,



**Figure 5. Representative MALDI-TOF MS Data of the HalA1-Xa or HalA2-Xa Cys-to-Ala Mutants Treated with HalM1 or HalM2**

The asterisks (\*) indicate phosphorylated products (Chatterjee et al., 2005a).

(A) HalA1-Xa C8A before (dashed line) and after incubation with HalM1 (solid line).


(B) HalA1-Xa C8A treated with TCEP/IAA before (dashed line) and after HalM1 (solid line).

(C) HalA2-Xa C5A before (dashed line) and after incubation with HalM2 (solid line).

(D) HalA2-Xa C5A treated with TCEP/PHMB before (dashed line) and after HalM2 treatment (solid line).

1996; Ottenwalder et al., 1995; van Kraaij et al., 2000). At present only limited information is available regarding the importance of the Lan and MeLan rings in each peptide of two-component lantibiotics. Ala scanning and random mutagenesis have been applied to the genes encoding the precursor peptides of lactacin 3147, resulting in a large amount of valuable data (Cotter et al., 2006; Field et al., 2007). However, the absence of bioactivity of several of the mutants involving the thioether rings resulted from abolished production and hence provided no direct information regarding their importance for activity. In the current study, a comprehensive examination of the importance of each (meth-

yl)lanthionine in haloduracin for biological activity was performed, taking advantage of its in vitro reconstituted biosynthesis. These experiments show that mutation of Cys17, Cys23, and Cys27 resulted in Hal $\alpha$  analogs in which the A, B, and C rings were disrupted, respectively, without any evidence that the remaining rings were not formed. The qualitative antimicrobial activity of these mutants shows that the C ring of Hal $\alpha$  is essential for activity. Its A ring is important but not essential, with a weak zone of inhibition observed, and the B ring is not required. The retention of bioactivity upon disrupting the B ring of Hal $\alpha$  was surprising given its high level of conservation in comparison with mersacidin



**Figure 6. Importance of Glu22 for Bioactivity**

(A) Structures of Hal $\alpha$ , lacticin 3147 A1, mersacidin, and actagardine. Residues colored green represent the proposed lipid II binding motif (CTLTXEC); the Glu residue is blue.


(B) HalA1-Xa E22Q before (dashed line) and after incubation with HalM1 (solid line). The asterisks (\*) indicate phosphorylated peptides (Chatterjee et al., 2005a).

(C) HalA1-Xa E22Q treated with TCEP/IAA before (dashed line) and after HalM1 (solid line).

(C ring; Chatterjee et al., 1992), actagardine (B ring; Zimmermann et al., 1995), and lacticin 3147 A1 (C ring; Ryan et al., 1999; Figure 6). These three lantibiotics bind to the peptidoglycan precursor lipid II (Brötz et al., 1998; Wiedemann et al., 2006; Zimmermann and Jung, 1997), and the CTLTXEC motif encompassing the conserved rings is believed to be important for this activity. For instance, alanine scanning mutagenesis carried out for lacticin 3147 A1 in vivo (Cotter et al., 2006) showed this region was highly sensitive to alteration with respect to bioactivity. In addition, when the C ring in lacticin 3147 A1 was opened, bioactivity was abolished (Cotter et al., 2006; Field et al., 2007). At present it

is not known why disruption of the B ring of Hal $\alpha$  is not detrimental to bioactivity, especially as the conserved Glu residue in the CTLTXEC motif is critical. The abolishment of antimicrobial activity for Hal $\alpha$  E22A and E22Q is in agreement with previous studies on mersacidin in which the Glu was substituted with Ala and antibiotic activity was lost (Szekat et al., 2003).

The qualitative SAR studies on Hal $\beta$  resulted in removal of its A–D rings. For the mutants disrupting the A, C, and D rings, the rings not targeted by mutagenesis were still formed by HalM2 according to the PHMB data, but mutation of Cys15 resulted in disruption of cyclization for other rings in addition to the B ring. These



**Figure 7. Proteolytic Processing of Haloduracin**

(A) HalA2-XaGS Q23A treated with HalM2 and Factor Xa resulted in GDVHAQ-Halβ Q23A. This peptide was used to monitor proteolytic processing. GDVHAQ-Halβ treated with supernatant of *L. lactis* CNRZ 117 (dashed line) or *B. halodurans* C-125 (solid line). GDVHAQ-Halβ Q23A calculated (calcd) 2883 Da; observed (obsd) 2886 Da. A TCEP adduct was observed at 3136 Da ( $\Delta m = 250$  Da, calcd 3133 Da) and is labeled with a double asterisk (\*\*). Halβ Q23A calcd 2276 Da; obsd 2281 Da. A TCEP adduct was observed at 2532 Da ( $\Delta m = 250$  Da, calcd 2526 Da) and is labeled with a double asterisk (\*\*). (B) HalA2-XaGS Q23A treated with HalM2 and then supernatant of *L. lactis* CNRZ 117 (dashed line), calcd 9290 Da ( $M + H - 7 H_2O$ ); obsd 9290 Da. HalA2-XaGS Q23A treated with HalM2 and then supernatant of *B. halodurans* C-125 (solid line), calcd 2276 Da (Halβ Q23A); obsd 2279 Da. (C) Halα isolated from *B. halodurans* C-125 was treated with TCEP/IAA. The resulting bisalkylated peptide was then incubated with supernatant of *L. lactis* CNRZ 117 (dashed line) or *B. halodurans* C-125 (solid line). Halα + 2 IAA calcd 3163 Da; obsd 3165 Da. Halα(Δ1-3) + IAA calcd 2745 Da; obsd 2748. Halα(Δ1-5) + IAA calcd 2468 Da; obsd 2469.

findings illustrate the danger of reaching conclusions regarding the importance of certain residues for bioactivity on the basis of mutagenesis studies without confirming that the mutation did not interfere with ring formation. Based on the experimental data, it can be concluded that the A ring in Halβ is dispensable and that the C and D rings are important but not essential. No conclusions can be made regarding the importance of the B ring because the observed lack of bioactivity of the Halβ C15A mutant could be due to disruption of multiple rings.

This study also provides some additional insights into proteolytic processing of haloduracin. Similar to the two-component lantibiotics cytolysin and plantaricin W (Cox et al., 2005; Holo et al., 2001), the mass of the mature Halβ peptide is smaller than that predicted by the cleavage site for the N-terminal protease domain of HalT. Additional proteolysis for cytolysin is carried out by a designated protease, termed CylA, which was shown to be necessary for antibiotic activity (Cox et al., 2005). No CylA homologs have been identified in the *B. halodurans* C-125 genome, yet six amino acids must be removed from the N terminus of the product that is expected to be secreted by HalT. The observed removal of these amino acids upon exposure to the supernatant of *B. halodurans* cell culture strongly suggests that one or more secreted proteases are responsible for this process. When Halα was first reduced, opening the disulfide ring at its N terminus, followed by alkylation of Cys1 and Cys8 with IAA, it too became susceptible to additional N-terminal proteolysis. Because the disulfide is shown not to be important for antimicrobial activity in haloduracin or in plantaricin W (Holo et al., 2001; McClarren et al., 2006), it may be conserved to protect the peptide from such degradation in the extracellular environment. Similarly, the N-terminal lanthionine in lacticin 3147 A1, which is also not required for antimicrobial activity (Cotter et al., 2006), may protect this compound from proteolysis. Interestingly, the great majority of the lantibiotics in the two-component class have cyclic structures at or near their N termini (Figure S6).

## SIGNIFICANCE

**This study is the first systematic analysis of the SAR of the individual thioether rings in a two-component lantibiotic.**



**Using an in vitro biosynthetic system, the C ring and Glu22 of Hal $\alpha$  of haloduracin are shown to be essential for antimicrobial activity with wild-type Hal $\beta$ . The A ring of Hal $\alpha$  is important but not essential, and surprisingly, given its high conservation in lantibiotics, the B ring is not required. The C and D rings of Hal $\beta$  were important but not absolutely required for its synergistic activity with wild-type Hal $\alpha$ . The disulfide ring present at the N terminus of Hal $\alpha$  is not important for its antimicrobial activity but protects the compound from proteolytic degradation by proteases secreted by the producer strain. Collectively, these findings provide new insights into the roles and importance of the crosslinks found in two-component lantibiotics. This study also highlights the value of using an in vitro biosynthetic system for SAR studies.**

## EXPERIMENTAL PROCEDURES

Construction of all overexpression plasmids and procedures for peptide purification are described in the Supplemental Data along with tables of all masses of the ions observed in the mass spectra shown in this work.

### Enzymatic Assays for Dehydration Activity

Purified HalA peptides were each dissolved in HalM assay buffer (50 mM Tris [pH 8.3] for HalA1 peptides and 50 mM MOPS [pH 7.2] for HalA2 peptides) to a final concentration of 0.3 mg/ml, and MgCl<sub>2</sub>, ATP, and TCEP were added to final concentrations of 10 mM, 2.5 mM, and 1 mM, respectively (final volume 20  $\mu$ l). Wild-type and mutant HalA1-Xa were incubated in separate reactions with HalM1; wild-type and mutant HalA2-Xa were incubated with HalM2 with a final enzyme concentration of ~0.2 mg/ml enzyme. Activity assays were incubated at 25°C for 3 hr and then quenched by addition of 5% TFA to a final concentration of 0.5% TFA and analyzed by MALDI-TOF MS. Samples were desalted prior to MS using 10  $\mu$ l C-18 ZipTip (Millipore; Billerica, MA) and eluted with 4  $\mu$ l of  $\alpha$ -hydroxyl cinnamic acid. From this solution, 3  $\mu$ l was applied to the MALDI-TOF MS target and analyzed.

### Evaluation of Cyclization Activity

For HalM1 assays, 1  $\mu$ l of 100 mM iodoacetamide (IAA) was added directly to 20  $\mu$ l of HalM1 assay (~5 mM final concentration) and incubated at 25°C for 90 min in the dark. For HalA1 starting material samples, 0.3 mg/ml peptide was incubated in 50 mM Tris [pH 8.3] supplemented with 1 mM TCEP for 20 min prior to addition of IAA, and the reaction was carried out as described. Samples were desalted by C-18 ZipTip (Millipore) and analyzed by MALDI-TOF MS. For HalM2 assays, 20  $\mu$ l aliquots were dried via centrivap and resuspended in 6  $\mu$ l of 10 mM TCEP and 4 M guanidine hydrochloride [pH 8]. Samples were incubated at 25°C for 20 min, 3  $\mu$ l of saturated *p*-hydroxymercuribenzoic acid (PHMB) solution was added, and the reaction mixture was incubated at 25°C for 2 hr in the dark. For HalA2 starting material samples, 0.3 mg/ml peptide was dried via centrivap and PHMB assays were carried out as described. Samples were checked for thiol modification by ZipTip (Millipore) desalting and eluting in 4  $\mu$ l of  $\alpha$ -hydroxyl cinnamic acid to run MALDI-TOF MS.

### Antibacterial Activity Assays

Larger-scale enzymatic assays (100  $\mu$ l) were carried out and then dried via centrivap. The products were resuspended in 100  $\mu$ l of Factor Xa cleavage buffer (20 mM HEPES [pH 8.0], 100 mM NaCl, 2 mM CaCl<sub>2</sub>), and 3  $\mu$ l of 1 mg/ml Factor Xa (New England Biolabs; Ipswich, MA) was added. Cleavage reactions were incubated at 25°C for 4 hr and analyzed by MALDI-TOF MS. Samples were dried by centrivap and resuspended in 5  $\mu$ l of sterile water. Any insoluble material was removed by centrifugation at 14 krpm for 5 min in a benchtop microcentrifuge. Solid agar diffusion assays were used to assess bactericidal activity. An overnight culture of a haloduracin-sensitive strain, *Lactococcus lactis* CNRZ 117 (Centre National de Recherches Zootechniques; Jouy-en-Josas, France), was grown in M17 medium (Difco) supplemented with 0.5% glucose at 30°C under static conditions for 15–20 hr. Plates were

prepared by addition of 500  $\mu$ l of 20% glucose (0.5% final concentration) and 150  $\mu$ l of dense culture to 20 ml of molten M17 agar (50°C) that was then allowed to solidify in a Petri dish at 25°C. Authentic haloduracin was isolated from *Bacillus halodurans* C-125 (American Type Culture Collection) as described previously (McClerren et al., 2006) and then further purified by RP-HPLC to separate Hal $\alpha$  and Hal $\beta$  (T. Oman and W.v.d.D., unpublished data). For positive control samples, purified Hal $\alpha$  and Hal $\beta$  peptides were combined in a 1:1 ratio (10  $\mu$ l each of 10  $\mu$ M solutions). For evaluation of the consequences of mutations, purified Hal $\alpha$  or Hal $\beta$  peptides (5  $\mu$ l of 10  $\mu$ M solution) were combined with in vitro prepared mutants (5  $\mu$ l concentrated HalM products from 100  $\mu$ l-scale assays). Samples were applied to small wells that were manually formed in the agar plate. The seeded strain was allowed to grow at 25°C for 12 hr, and antibacterial activity was qualitatively determined by the presence or absence of a growth inhibition zone.

### Proteolytic Processing

HalA2-XaGS and HalA2-XaGS Q23A were incubated with HalM2 and treated with Factor Xa (50  $\mu$ l scale). The resulting products, GDVHAQ-Hal $\beta$  and GDVHAQ-Hal $\beta$  Q23A, were analyzed for antimicrobial activity using solid agar diffusion assays as described. To test if the six N-terminal amino acids are removed by an external protease, these products were incubated with the cell-free supernatants from *B. halodurans* C-125 and *L. lactis* CNRZ 117 cultures. *B. halodurans* C-125 was grown in brain heart infusion (BHI) medium (Bacto or BBL) for 96 hr at 30°C with vigorous agitation. Cultures were centrifuged (5000  $\times$  g, 10 min), and cell-free supernatant was used for assays with GDVHAQ-Hal $\beta$  Q23A. In addition, the cells were washed with 1 M NaCl. After centrifugation, the cell-free 1 M NaCl wash was also used for assay with GDVHAQ-Hal $\beta$  Q23A. Production of haloduracin from GDVHAQ-Hal $\beta$  Q23A was analyzed by MALDI-TOF MS. Both the cell-free supernatant and the 1 M NaCl wash contained proteolytic activity as discussed in Results. *L. lactis* CNRZ 117 was grown as described and its culture supernatant was used for analogous experiments as described for *B. halodurans*. Identical procedures were also used to monitor proteolytic processing of Hal $\alpha$  and HalM2-processed HalA2.

## SUPPLEMENTAL DATA

Supplemental Data include Supplemental Experimental Procedures, Supplemental References, and six figures and can be found with this article online at <http://www.chembiol.com/cgi/content/full/15/10/1035/DC1/>.

## ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health Grant GM58822. L.E.C. was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award 5 T32 GM070421 from the National Institute of General Medical Sciences.

Received: June 10, 2008  
Revised: July 24, 2008  
Accepted: July 28, 2008  
Published: October 17, 2008

## REFERENCES

- Bierbaum, G., Szekat, C., Josten, M., Heidrich, C., Kempter, C., Jung, G., and Sahl, H.G. (1996). Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. *Appl. Environ. Microbiol.* 62, 385–392.
- Brötz, H., Bierbaum, G., Leopold, K., Reynolds, P.E., and Sahl, H.G. (1998). The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. *Antimicrob. Agents Chemother.* 42, 154–160.
- Castiglione, F., Lazzarini, A., Carrano, L., Corti, E., Ciciliato, I., Gastaldo, L., Candiani, P., Losi, D., Marinelli, F., Selva, E., et al. (2008). Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. *Chem. Biol.* 15, 22–31.
- Chatterjee, S., Chatterjee, S., Lad, S.J., Phansalkar, M.S., Rupp, R.H., Ganguli, B.N., Fehlhaber, H.W., and Kogler, H. (1992). Mersacidin, a new antibiotic

- from *Bacillus*. Fermentation, isolation, purification and chemical characterization. *J. Antibiot. (Tokyo)* **45**, 832–838.
- Chatterjee, C., Miller, L.M., Leung, Y.L., Xie, L., Yi, M., Kelleher, N.L., and van der Donk, W.A. (2005a). Lactacin 481 synthetase phosphorylates its substrate during lantibiotic production. *J. Am. Chem. Soc.* **127**, 15332–15333.
- Chatterjee, C., Paul, M., Xie, L., and van der Donk, W.A. (2005b). Biosynthesis and mode of action of lantibiotics. *Chem. Rev.* **105**, 633–684.
- Chatterjee, C., Patton, G.C., Cooper, L., Paul, M., and van der Donk, W.A. (2006). Engineering dehydro amino acids and thioethers into peptides using lactacin 481 synthetase. *Chem. Biol.* **13**, 1109–1117.
- Chen, P., Novak, J., Kirk, M., Barnes, S., Qi, F., and Caufield, P.W. (1998). Structure-activity study of the lantibiotic mutacin II from *Streptococcus mutans* T8 by a gene replacement strategy. *Appl. Environ. Microbiol.* **64**, 2335–2340.
- Chen, P., Qi, F.X., Novak, J., Krull, R.E., and Caufield, P.W. (2001). Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II. *FEMS Microbiol. Lett.* **195**, 139–144.
- Corvey, C., Stein, T., Dusterhus, S., Karas, M., and Entian, K.D. (2003). Activation of subtilin precursors by *Bacillus subtilis* extracellular serine proteases subtilisin (AprE), WprA, and Vpr. *Biochem. Biophys. Res. Commun.* **304**, 48–54.
- Cotter, P.D., Hill, C., and Ross, R.P. (2005). Bacterial lantibiotics: strategies to improve therapeutic potential. *Curr. Protein Pept. Sci.* **6**, 61–75.
- Cotter, P.D., Deegan, L.H., Lawton, E.M., Draper, L.A., O'Connor, P.M., Hill, C., and Ross, R.P. (2006). Complete alanine scanning of the two-component lantibiotic lactacin 3147: generating a blueprint for rational drug design. *Mol. Microbiol.* **62**, 735–747.
- Cox, C.R., Coburn, P.S., and Gilmore, M.S. (2005). Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. *Curr. Protein Pept. Sci.* **6**, 77–84.
- Delves-Broughton, J., Blackburn, P., Evans, R.J., and Hugenholz, J. (1996). Applications of the bacteriocin, nisin. *Antonie Van Leeuwenhoek* **69**, 193–202.
- Field, D., Collins, B., Cotter, P.D., Hill, C., and Ross, R.P. (2007). A system for the random mutagenesis of the two-peptide lantibiotic lactacin 3147: analysis of mutants producing reduced antibacterial activities. *J. Mol. Microbiol. Biotechnol.* **13**, 226–234.
- Furgerson Ihnken, L.A., Chatterjee, C., and van der Donk, W.A. (2008). In vitro reconstitution and substrate specificity of a lantibiotic protease. *Biochemistry* **47**, 7352–7363.
- Galvin, M., Hill, C., and Ross, R.P. (1999). Lactacin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays. *Lett. Appl. Microbiol.* **28**, 355–358.
- Garneau, S., Martin, N.I., and Vederas, J.C. (2002). Two-peptide bacteriocins produced by lactic acid bacteria. *Biochimie* **84**, 577–592.
- Håvarstein, L.S., Diep, D.B., and Nes, I.F. (1995). A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export. *Mol. Microbiol.* **16**, 229–240.
- Holo, H., Jeknic, Z., Daeschel, M., Stevanovic, S., and Nes, I.F. (2001). Plantaricin W from *Lactobacillus plantarum* belongs to a new family of two-peptide lantibiotics. *Microbiology* **147**, 643–651.
- Hsu, S.T., Breukink, E., Bierbaum, G., Sahl, H.G., de Kruijff, B., Kaptein, R., van Nuland, N.A., and Bonvin, A.M. (2003). NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. *J. Biol. Chem.* **278**, 13110–13117.
- Hyink, O., Balakrishnan, M., and Tagg, J.R. (2005). *Streptococcus rattus* strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. *FEMS Microbiol. Lett.* **252**, 235–241.
- Kruszewska, D., Sahl, H.G., Bierbaum, G., Pag, U., Hynes, S.O., and Ljungh, A. (2004). Mersacidin eradicates methicillin-resistant *Staphylococcus aureus* (MRSA) in a mouse rhinitis model. *J. Antimicrob. Chemother.* **54**, 648–653.
- Kuipers, O.P., Bierbaum, G., Ottenwälder, B., Dodd, H.M., Horn, N., Metzger, J., Kupke, T., Gnau, V., Bongers, R., van den Bogaard, P., et al. (1996). Protein engineering of lantibiotics. *Antonie Van Leeuwenhoek* **69**, 161–169.
- Lawton, E.M., Cotter, P.D., Hill, C., and Ross, R.P. (2007). Identification of a novel two-peptide lantibiotic, Haloduracin, produced by the alkaliphile *Bacillus halodurans* C-125. *FEMS Microbiol. Lett.* **267**, 64–71.
- Levengood, M.R., Patton, G.C., and van der Donk, W.A. (2007). The leader peptide is not required for post-translational modification by lactacin 481 synthetase. *J. Am. Chem. Soc.* **129**, 10314–10315.
- Li, B., and van der Donk, W.A. (2007). Identification of essential catalytic residues of the cyclase NisC involved in the biosynthesis of nisin. *J. Biol. Chem.* **282**, 21169–21175.
- Li, B., Yu, J.-P.J., Brunzelle, J.S., Moll, G.N., van der Donk, W.A., and Nair, S.K. (2006). Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. *Science* **311**, 1464–1467.
- Lubelski, J., Rink, R., Khusainov, R., Moll, G.N., and Kuipers, O.P. (2008). Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. *Cell. Mol. Life Sci.* **65**, 455–476.
- Martin, N.I., Sprules, T., Carpenter, M.R., Cotter, P.D., Hill, C., Ross, R.P., and Vederas, J.C. (2004). Structural characterization of lactacin 3147, a two-peptide lantibiotic with synergistic activity. *Biochemistry* **43**, 3049–3056.
- McClerren, A.L., Cooper, L.E., Quan, C., Thomas, P.M., Kelleher, N.L., and van der Donk, W.A. (2006). Discovery and in vitro biosynthesis of haloduracin, a new two-component lantibiotic. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 17243–17248.
- Morgan, S.M., O'Connor, P.M., Cotter, P.D., Ross, R.P., and Hill, C. (2005). Sequential actions of the two component peptides of the lantibiotic lactacin 3147 explain its antimicrobial activity at nanomolar concentrations. *Antimicrob. Agents Chemother.* **49**, 2606–2611.
- Nes, I.F., and Tagg, J.R. (1996). Novel lantibiotics and their pre-peptides. *Antonie Van Leeuwenhoek* **69**, 89–97.
- Ottenwälder, B., Kupke, T., Brecht, S., Gnau, V., Metzger, J., Jung, G., and Götz, F. (1995). Isolation and characterization of genetically engineered gallidermin and epidermin analogs. *Appl. Environ. Microbiol.* **61**, 3894–3903.
- Patton, G.C., Paul, M., Cooper, L.E., Chatterjee, C., and van der Donk, W.A. (2008). The importance of the leader sequence for directing lanthionine formation in lactacin 481. *Biochemistry* **47**, 7342–7351.
- Paul, M., Patton, G.C., and van der Donk, W.A. (2007). Mutants of the zinc ligands of lactacin 481 synthetase retain dehydration activity but have impaired cyclization activity. *Biochemistry* **46**, 6268–6276.
- Petersen, F.C., Fimland, G., and Scheie, A.A. (2006). Purification and functional studies of a potent modified quorum-sensing peptide and a two-peptide bacteriocin in *Streptococcus mutans*. *Mol. Microbiol.* **61**, 1322–1334.
- Pitts, K.E., and Summers, A.O. (2002). The roles of thiols in the bacterial organomercurial lyase (MerB). *Biochemistry* **41**, 10287–10296.
- Rink, R., Kuipers, A., de Boef, E., Leenhouts, K.J., Driessen, A.J., Moll, G.N., and Kuipers, O.P. (2005). Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. *Biochemistry* **44**, 8873–8882.
- Ryan, M.P., Jack, R.W., Josten, M., Sahl, H.G., Jung, G., Ross, R.P., and Hill, C. (1999). Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lactacin 3147. *J. Biol. Chem.* **274**, 37544–37550.
- Szekat, C., Jack, R.W., Skutlarek, D., Farber, H., and Bierbaum, G. (2003). Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. *Appl. Environ. Microbiol.* **69**, 3777–3783.
- van der Meer, J.R., Rollema, H.S., Siezen, R.J., Beerthuyzen, M.M., Kuipers, O.P., and de Vos, W.M. (1994). Influence of amino acid substitutions in the nisin leader peptide on biosynthesis and secretion of nisin by *Lactococcus lactis*. *J. Biol. Chem.* **269**, 3555–3562.
- van Kraaij, C., Breukink, E., Rollema, H.S., Bongers, R.S., Kosters, H.A., de Kruijff, B., and Kuipers, O.P. (2000). Engineering a disulfide bond and free thiols in the lantibiotic nisin Z. *Eur. J. Biochem.* **267**, 901–909.
- Wiedemann, I., Bottiger, T., Bonelli, R.R., Wiese, A., Hage, S.O., Gutschmann, T., Seydel, U., Deegan, L., Hill, C., Ross, P., et al. (2006). The mode of action of the lantibiotic lactacin 3147—a complex mechanism involving specific

interaction of two peptides and the cell wall precursor lipid II. *Mol. Microbiol.* *61*, 285–296.

Wiley, J.M., and van der Donk, W.A. (2007). Lantibiotics: peptides of diverse structure and function. *Annu. Rev. Microbiol.* *61*, 477–501.

Xie, L., Miller, L.M., Chatterjee, C., Averin, O., Kelleher, N.L., and van der Donk, W.A. (2004). Lactacin 481: in vitro reconstitution of lantibiotic synthetase activity. *Science* *303*, 679–681.

Yonezawa, H., and Kuramitsu, H.K. (2005). Genetic analysis of a unique bacteriocin, Smb, produced by *Streptococcus mutans* GS5. *Antimicrob. Agents Chemother.* *49*, 541–548.

Zimmermann, N., and Jung, G. (1997). The three-dimensional solution structure of the lantibiotic murein-biosynthesis-inhibitor actagardine determined by NMR. *Eur. J. Biochem.* *246*, 809–819.

Zimmermann, N., Metzger, J.W., and Jung, G. (1995). The tetracyclic lantibiotic actagardine.  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR assignments and revised primary structure. *Eur. J. Biochem.* *228*, 786–797.